Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes
To access this article, please choose from the options below
PII: S0145-2126(09)00154-4
doi:10.1016/j.leukres.2009.03.027
© 2009 Elsevier Ltd. All rights reserved.
